🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,387 results for “Le” Clear

  1. Sogroya 15 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen, Norditropin FlexPro, injektionsvæske, opløsning i fyldt pen

    NovoThirteen

    Growth Hormone Deficiency in children

    phase 3 small molecule active

    1 trial

  2. Solriamfetol

    Ignis Therapeutics (Suzhou) Limited

    Sleep Apnea, Obstructive

    phase 3 small molecule completed

    1 trial

  3. Solriamfetol 150 MG

    Axsome Therapeutics

    Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms

    phase 3 small molecule active

    1 trial

  4. Solriamfetol 150 mg

    Axsome Therapeutics

    Excessive Sleepiness

    phase 3 small molecule active

    1 trial

  5. Solution for Injection, subcutaneous Use, IMCIVREE 10 mg/ml solution for injection

    Lacuna Pharma Pty Ltd

    Improper function of certain messenger materials in the body that control body weight and hunger in people

    phase 3 small molecule active

    1 trial

  6. Solution for injection in pre-filled syringe without Ustekinumab 90, Solution for injection without Ustekinumab 45, STELARA 45 mg solution for injection, STELARA 90 mg solution for injection in pre-filled syringe, JNJ-77242113, Film-Coated Tablet without JNJ-77242113

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  7. Sonelokimab, Placebo is a sterile solution in a single use prefilled syringe (PFS) intended for subcutaneous administration

    MoonLake Immunotherapeutics

    hidradenitis suppurativa (HS)

    phase 3 small molecule active

    1 trial

  8. Sonelokimab, Placebo is a sterile solution in a single use prefilled syringe (PFS) intended for subcutaneous administration

    MoonLake Immunotherapeutics

    hidradenitis suppurativa (HS)

    phase 3 small molecule active

    1 trial

  9. Sonelokimab, Placebo is a sterile solution in a single use prefilled syringe (pfs) intended for subcutaneous administration

    MoonLake Immunotherapeutics

    Psoriatic arthritis

    phase 3 small molecule active

    1 trial

  10. Sonrotoclax

    BEONE MEDICINES AUS PTY LTD

    Mantle Cell Lymphoma

    phase 3 small molecule active

    1 trial

  11. Sonrotoclax

    BEONE MEDICINES AUS PTY LTD

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    4 trials

  12. Sorafenib

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule completed

    1 trial

  13. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Diabetic Nephropathies

    phase 3 small molecule active

    1 trial

  14. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Heart Failure

    phase 3 small molecule terminated

    2 trials

  15. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes Mellitus (T1DM)

    phase 3 small molecule completed

    1 trial

  16. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule terminated

    3 trials

  17. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Obstructive Cardiomyopathy, Hypertrophic

    phase 3 small molecule active

    1 trial

  18. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes Mellitus

    phase 3 small molecule completed

    3 trials

  19. Sotagliflozin (SAR439954)

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    4 trials

  20. Sotagliflozin Low Dose

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes (T1D)

    phase 3 small molecule active

    1 trial

  21. Soticlestat

    Takeda

    Dravet Syndrome (DS)

    phase 3 small molecule terminated

    3 trials

  22. Sparsentan_DF2, IRBESARTAN, Sparsentan_DF3

    Travere Therapeutics

    Focal segmental glomerulosclerosis (FSGS)

    phase 3 small molecule active

    1 trial

  23. Spravato 28 mg nasal spray, solution, Midazolam-ratiopharm® 2 mg/ml orale Lösung, Oral placebo, Intranasal Placebo

    Janssen-Cilag International N.V.

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  24. Standard First-Line Therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Unresectable Colorectal Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources